| Identification | Back Directory | [Name]
TENOVIN-1 | [CAS]
380315-80-0 | [Synonyms]
CS-571
TENOVIN-1
Tenovin-1, >=98%
TENOVIN-1;TENOVIN 1
TENOVIN-1 USP/EP/BP
N-[(4-acetaMidophenyl)carbaMothioyl]-4-tert-butylbenzaMide
N-[[[4-(Acetylamino)phenyl]amino]thioxomethyl]-4-(1,1-dimethylethyl)benzamide
Benzamide, N-[[[4-(acetylamino)phenyl]amino]thioxomethyl]-4-(1,1-dimethylethyl)-
N-[[[4-(Acetylamino)phenyl]amino]thioxomethyl]-4-(1,1-dimethylethyl)benzamide Tenovin 1
Tenovin 1 N-[[[4-(Acetylamino)phenyl]amino]thioxomethyl]-4-(1,1-dimethylethyl)benzamide | [EINECS(EC#)]
200-256-5 | [Molecular Formula]
C20H23N3O2S | [MDL Number]
MFCD02914760 | [MOL File]
380315-80-0.mol | [Molecular Weight]
369.487 |
| Chemical Properties | Back Directory | [Melting point ]
>180°C (Subl.) | [density ]
1.238±0.06 g/cm3(Predicted) | [storage temp. ]
Store at +4°C | [solubility ]
Soluble in DMSO (10 mg/ml with warming) | [form ]
solid | [pka]
9.09±0.70(Predicted) | [color ]
White | [Stability:]
Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| Hazard Information | Back Directory | [Description]
Tenovin-1 is a small molecule activator of p53 transcriptional activity. At 10 μM, it elevates p53 expression in MCF-7 cells within two hours of treatment and longer-term exposure significantly decreases the growth of BL2 Burkitt’s lymphoma and ARN8 melanoma cells.1 Functioning upstream of p53, tenovin-1 acts by inhibiting the deacetylase activity of purified human SIRT1 and SIRT2, members of NAD+-dependent class III histone deacetylases that belong to the sirtuin family.1 While tenovin-1 demonstrates low genotoxicity, the compound has poor water solubility, which limits its uses in vivo. | [Uses]
Tenovin 1 is a sirtuin inhibitor. | [Definition]
ChEBI: N-[(4-acetamidoanilino)-sulfanylidenemethyl]-4-tert-butylbenzamide is a member of thioureas. | [Biological Activity]
p53 activator that protects against MDM2-mediated p53 degradation. Elevates levels of p53 and p21 CIP/WAF1 and induces expression from an endogenous p53-dependent promoter. Exhibits potent antiproliferative activity in vitro . | [References]
Lain et al. (2008), Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator; Cancer Cell, 13 454
Sonnemann et al. (2014), p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors; Br. J. Cancer 110 656
Nihal et al. (2014), SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis; Cell Cycle 13 632
Wilking et al. (2014), SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation; Arch. Biochem. Biophys. 563 94
Marx et al. (2018), The sirtuin 1/2 inhibitor tenovin-1 induces a nonlinear apoptosis-inducing factor-dependent cell death in a p53 null Ewing’s sarcoma cell line; New Drugs 36 396
Bang et al. (2019), Tenovin-1 Induces Senescence and Decreases Wound-Healing Activity in Cultured Rat Primary Astrocytes; Biomol. Ther. (Seoul) 27 283 |
|
|